Brokerages Expect Globus Medical Inc (GMED) Will Post Quarterly Sales of $185.39 Million

Analysts expect that Globus Medical Inc (NYSE:GMED) will report $185.39 million in sales for the current quarter, according to Zacks Investment Research. Three analysts have provided estimates for Globus Medical’s earnings, with the highest sales estimate coming in at $186.86 million and the lowest estimate coming in at $182.60 million. Globus Medical reported sales of $174.41 million in the same quarter last year, which indicates a positive year over year growth rate of 6.3%. The company is scheduled to announce its next earnings report on Wednesday, May 1st.

On average, analysts expect that Globus Medical will report full-year sales of $769.96 million for the current financial year, with estimates ranging from $769.02 million to $770.50 million. For the next year, analysts expect that the firm will post sales of $833.16 million, with estimates ranging from $812.67 million to $856.00 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that cover Globus Medical.

Globus Medical (NYSE:GMED) last posted its earnings results on Thursday, February 21st. The medical device company reported $0.43 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.40 by $0.03. Globus Medical had a net margin of 21.95% and a return on equity of 15.22%. The company had revenue of $195.94 million during the quarter, compared to the consensus estimate of $195.50 million.

GMED has been the topic of several recent research reports. Zacks Investment Research lowered Globus Medical from a “hold” rating to a “sell” rating in a report on Thursday, February 28th. Oppenheimer reissued a “hold” rating on shares of Globus Medical in a report on Tuesday, March 19th. Credit Suisse Group started coverage on Globus Medical in a report on Monday, December 17th. They set an “outperform” rating and a $53.00 price objective on the stock. ValuEngine downgraded Globus Medical from a “buy” rating to a “hold” rating in a research note on Tuesday, March 5th. Finally, UBS Group upgraded Globus Medical from a “neutral” rating to a “buy” rating and set a $55.00 target price for the company in a report on Thursday, February 28th. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and six have given a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $56.36.

In other Globus Medical news, SVP Kelly Huller sold 3,000 shares of Globus Medical stock in a transaction that occurred on Thursday, March 28th. The stock was sold at an average price of $48.59, for a total value of $145,770.00. Following the transaction, the senior vice president now directly owns 12,384 shares of the company’s stock, valued at approximately $601,738.56. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, President Anthony L. Williams sold 212,082 shares of Globus Medical stock in a transaction that occurred on Thursday, March 7th. The stock was sold at an average price of $46.83, for a total value of $9,931,800.06. Following the completion of the transaction, the president now directly owns 89,583 shares in the company, valued at $4,195,171.89. The disclosure for this sale can be found here. Insiders have sold 426,852 shares of company stock valued at $20,061,774 over the last 90 days. Corporate insiders own 28.44% of the company’s stock.

Several institutional investors have recently made changes to their positions in GMED. Investec Asset Management LTD bought a new position in Globus Medical during the fourth quarter worth $64,761,000. Oregon Public Employees Retirement Fund boosted its holdings in Globus Medical by 4,284.6% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 1,250,619 shares of the medical device company’s stock valued at $29,000 after purchasing an additional 1,222,096 shares during the period. Norges Bank acquired a new stake in Globus Medical in the 4th quarter worth $43,840,000. Marshall Wace LLP acquired a new stake in Globus Medical in the 3rd quarter worth $48,854,000. Finally, BlackRock Inc. grew its position in Globus Medical by 2.8% in the 3rd quarter. BlackRock Inc. now owns 9,456,276 shares of the medical device company’s stock worth $536,739,000 after purchasing an additional 254,550 shares during the last quarter. Institutional investors and hedge funds own 69.27% of the company’s stock.

Shares of GMED stock traded up $0.40 on Monday, hitting $48.24. The company’s stock had a trading volume of 456,695 shares, compared to its average volume of 592,647. Globus Medical has a fifty-two week low of $38.01 and a fifty-two week high of $57.83. The firm has a market cap of $4.72 billion, a PE ratio of 28.89, a PEG ratio of 2.44 and a beta of 0.86.

Globus Medical Company Profile

Globus Medical, Inc, a medical device company, focuses on the design, development, and commercialization of musculoskeletal implants that promote healing in patients with spine disorders. The company offers products that address a variety of musculoskeletal pathologies, anatomies, and surgical approaches.

Further Reading: Roth IRA

Get a free copy of the Zacks research report on Globus Medical (GMED)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Globus Medical (NYSE:GMED)

Receive News & Ratings for Globus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Globus Medical and related companies with MarketBeat.com's FREE daily email newsletter.